I used my long blog on this topic as input for a 3 minute video script.
There are several scripts below, the first entirely neutral (or FDA favorable, based on FDA talking points.) The second and third are progressively more tilted to a lab industry concerned about regulation. The final fourth script is shrill and loudly protests against the proposed regulation which is portrayed as all-bad.
We lighten up with a bonus, a monolog a la' Louis Black. Then, a final 5 minute, longer script in journalistic style, pretty close to one that could actually be used.
###
[INPUT: BLOG AND REQUEST FOR 3 MINUTE SCRIPT]
CHAT GPT
Certainly, I can help you create a 3-minute video script based on the provided blog article. Here's a script that covers the key points:
#1 ==========================================
[Opening Shot]
[Background Music]
Narrator (Voiceover): "On September 29, 2023, the FDA unveiled a long-awaited regulation that could reshape the landscape of laboratory-developed tests."
[Cut to Images of FDA Building and the Rule Document]
Narrator (Voiceover): "The rule, which had been eagerly anticipated, was released in typescript form, with the official publication in the Federal Register scheduled for October 3."
[Transition to Graphics of the FDA Press Release and Federal Register Rule Page]
Narrator (Voiceover): "For laboratory and FDA policy experts, this regulation marks a significant milestone in the lab-developed test industry."
[Cut to Image of FDA Leadership]
Narrator (Voiceover): "It's the result of the FDA's clear stance that they would step in with regulation if Congress didn't pass specific legislation, such as the VALID Act."
[Zoom in on the Core Change]
Narrator (Voiceover): "But what exactly does this regulation entail? At its core, it's a micro regulatory change."
[Show Rule Text]
Narrator (Voiceover): "The FDA explicitly defines a test as an in vitro diagnostic device (IVD) when its manufacturer is a laboratory."
[Transition to Marketing Claims]
Narrator (Voiceover): "The regulation, however, isn't just about definitions. It also addresses marketing claims and performance, giving substantial weight to both."
[Show Section on Costs and Benefits]
Narrator (Voiceover): "The FDA estimates the financial benefits could range from 2 to 86 billion dollars, with the best estimate at 22 billion dollars."
[Cut to FDA Justification]
Narrator (Voiceover): "The FDA's justification for this change is extensive. It cites concerns about under-regulation in certain testing areas, especially non-invasive prenatal screening (NIPS)."
[Show FDA Concerns]
Narrator (Voiceover): "The agency has witnessed a surge in the volume, complexity, and scope of IVDs offered as LDTs, particularly in cancer treatment decision-making."
[Transition to Compliance]
Narrator (Voiceover): "As for compliance, the FDA's proposed phased approach outlines five stages."
[Show Timeline]
Narrator (Voiceover): "These stages range from ending enforcement discretion for Medical Device Reporting to premarket review requirements."
[Show Third-Party Review]
Narrator (Voiceover): "Laboratories can also consider third-party review programs, potentially streamlining the process."
[Transition to Economic Impact]
Narrator (Voiceover): "The rule includes a detailed economic analysis, assessing potential costs and benefits."
[Show Benefits]
Narrator (Voiceover): "The goal? Ensuring the safety and effectiveness of LDTs, addressing concerns about their quality and performance."
[Cut to Risk Categories]
Narrator (Voiceover): "The FDA categorizes LDTs into risk categories, differentiating between high-risk and moderate to low-risk tests."
[Show Timeline]
Narrator (Voiceover): "This approach allows the FDA to prioritize high-risk tests while giving labs time to comply with regulatory requirements."
[Closing Shot]
Narrator (Voiceover): "In summary, the FDA's new regulation may bring substantial changes to the laboratory-developed test industry. Stay tuned as this policy unfolds."
[Background Music Fades]
This script provides an overview of the key points from your blog article and can serve as a basis for creating a 3-minute video. You can add visuals, graphics, and additional details as needed to complement the narration.
User
That's fair, and very even handed.
However, most of the viewers of the video will be from the lab industry and will be opposed to more regulatory costs and burdens. Could you write the script with that audience in mind, however, still maintaining a mostly neutral tone.
It should still be even handed journalism, just considering that the audience will not be so pleased and will be interested in their options for comment periods and the possibility of court challenges to slow down the change.
ChatGPT
Of course, I can provide a script with a focus on the lab industry's perspective while maintaining a balanced tone. Here's a revised script:
#2 ==========================================
[Opening Shot]
[Background Music]
Narrator (Voiceover): "On September 29, 2023, the FDA unveiled a long-anticipated regulation that's poised to impact the lab-developed test industry."
[Cut to Images of FDA Building and the Rule Document]
Narrator (Voiceover): "But for those within the laboratory industry, this regulation brings both challenges and opportunities."
[Transition to Graphics of the FDA Press Release and Federal Register Rule Page]
Narrator (Voiceover): "The FDA's announcement comes after months of speculation, with the official publication in the Federal Register scheduled for October 3."
[Cut to Image of FDA Leadership]
Narrator (Voiceover): "Many within the lab industry had been watching closely, especially as the FDA had made it clear that if Congress didn't pass specific legislation, such as the VALID Act, they would step in with regulation."
[Zoom in on the Core Change]
Narrator (Voiceover): "So, what's the core change? At its heart, it's a micro regulatory shift."
[Show Rule Text]
Narrator (Voiceover): "The FDA now explicitly defines a test as an in vitro diagnostic device (IVD) when its manufacturer is a laboratory."
[Transition to Marketing Claims]
Narrator (Voiceover): "But this regulation isn't just about definitions. It also delves into marketing claims and performance, factors that have raised concerns."
[Show Section on Costs and Benefits]
Narrator (Voiceover): "The FDA estimates the financial benefits could range from 2 to 86 billion dollars, with the best estimate at 22 billion dollars."
[Cut to FDA Justification]
Narrator (Voiceover): "The FDA's justification for this change is extensive. It cites concerns about under-regulation in certain testing areas, especially non-invasive prenatal screening (NIPS)."
[Show FDA Concerns]
Narrator (Voiceover): "Additionally, the agency has seen a surge in the volume, complexity, and scope of IVDs offered as LDTs, particularly in cancer treatment decision-making."
[Transition to Compliance]
Narrator (Voiceover): "Now, let's talk compliance. The FDA's proposed phased approach outlines five stages."
[Show Timeline]
Narrator (Voiceover): "These stages range from ending enforcement discretion for Medical Device Reporting to premarket review requirements."
[Show Third-Party Review]
Narrator (Voiceover): "One option for labs is to consider third-party review programs, which could streamline the process."
[Transition to Economic Impact]
Narrator (Voiceover): "The rule includes a detailed economic analysis, assessing potential costs and benefits."
[Show Benefits]
Narrator (Voiceover): "The goal? Ensuring the safety and effectiveness of LDTs, addressing concerns about their quality and performance."
[Cut to Risk Categories]
Narrator (Voiceover): "The FDA categorizes LDTs into risk categories, differentiating between high-risk and moderate to low-risk tests."
[Show Timeline]
Narrator (Voiceover): "This approach allows the FDA to prioritize high-risk tests while giving labs time to comply with regulatory requirements."
[Closing Shot]
Narrator (Voiceover): "In summary, the FDA's new regulation presents a mixed bag for the laboratory industry. As they assess its impact, they may explore options for comment periods and even consider legal challenges to influence the pace of change."
[Background Music Fades]
This revised script maintains a neutral and even-handed tone while focusing on the lab industry's perspective, acknowledging their concerns and potential courses of action. It provides a balanced view of the situation for viewers within the lab industry.
User
Ok that's a great benchmark and exactly what I asked for.
Could we now do a script more favorable to the current lab inidustry, raising concerns about costs ($5B for the lab industry), swamping the FDA's staff with high numbers of applications, and impairing innovation by adding regulation. The FDA seems to have written this to stack arguments in its favor, and in favor of more regulation, but it's not a full picture if the public only reads the FDA's own story and not a multi stakeholder view.
ChatGPT
Certainly, I can provide a script that highlights concerns from the current lab industry perspective, focusing on potential costs, regulatory burdens, and their impact on innovation. Here's the script with that angle:
#3 ==========================================
[Opening Shot]
[Background Music]
Narrator (Voiceover): "On September 29, 2023, the FDA introduced a new regulation that's poised to reshape the lab-developed test industry."
[Cut to Images of Lab Facilities and Lab Technicians]
Narrator (Voiceover): "For those within the lab industry, this regulation raises some serious concerns."
[Transition to Graphics of FDA Announcement and Rule Document]
Narrator (Voiceover): "After months of anticipation, the FDA's regulation was officially announced, with publication in the Federal Register scheduled for October 3."
[Cut to Image of Concerned Lab Executive]
Narrator (Voiceover): "Many leaders in the lab industry have been watching closely, and their concerns are growing."
[Zoom in on the Core Change]
Narrator (Voiceover): "At its core, this regulation signifies a significant shift in regulatory oversight."
[Show Rule Text]
Narrator (Voiceover): "The FDA now explicitly classifies tests as in vitro diagnostic devices (IVDs) when the manufacturer is a laboratory."
[Transition to Regulatory Burdens]
Narrator (Voiceover): "But what's causing unease? Regulatory burdens and their potential consequences."
[Show Section on Costs and Benefits]
Narrator (Voiceover): "The FDA estimates that compliance costs for the lab industry could soar to a staggering 5 billion dollars."
[Cut to Concerned Lab Professionals]
Narrator (Voiceover): "These costs, coupled with the sheer volume of applications expected to flood the FDA, could overwhelm their staff."
[Transition to Impact on Innovation]
Narrator (Voiceover): "Innovation is also at stake. The lab industry fears that this added layer of regulation might stifle creativity."
[Show FDA Justification]
Narrator (Voiceover): "While the FDA cites concerns about under-regulation, many within the lab industry argue that existing quality control measures are robust."
[Transition to Compliance Challenges]
Narrator (Voiceover): "Compliance with the proposed phased approach brings its own set of challenges."
[Show Timeline]
Narrator (Voiceover): "These stages range from ending enforcement discretion to premarket review requirements, raising questions about feasibility."
[Cut to Lab Innovators]
Narrator (Voiceover): "Innovation thrives in environments that encourage experimentation and advancement. Some fear that these new regulations could hinder that spirit."
[Closing Shot]
Narrator (Voiceover): "In summary, the FDA's regulation presents a complex landscape for the lab industry. The concerns over costs, potential staff overload, and impacts on innovation are very real."
[Background Music Fades]
This script offers a viewpoint from the current lab industry perspective, emphasizing their concerns about costs, regulatory burdens, and potential impacts on innovation. It maintains an even-handed tone while highlighting these industry-specific worries.
Great. Now a 3 minute script, that is from a group representing the lab industry, opposed to any new regulation, and views this is a land grab by FDA for overzealous regulators. The FDA can't possibly staff up to regulate thousands or tens of thousands of test, and their revisions, and doesn't even pretent to have a plan to do so. Billions in costs are unaccounted for, and the severe damage to lab industry innovation via LDT tests, will be tragic. Continue in this vein.
#4 (Hostile) ==========================================
ChatGPT
Certainly, here's a 3-minute script from the perspective of a group representing the lab industry, strongly opposed to the new regulation and expressing concerns about the FDA's ability to implement it effectively:
[Opening Shot]
[Background Music]
Narrator (Voiceover): "In the world of laboratory-developed tests (LDTs), a storm is brewing, and the lab industry is raising its voice."
[Cut to Images of Lab Facilities and Lab Technicians]
Narrator (Voiceover): "The FDA's recent regulatory proposal is causing quite a stir, and not in a good way."
[Transition to FDA Announcement Graphics]
Narrator (Voiceover): "With the FDA's announcement fresh in everyone's minds, the lab industry has some serious reservations."
[Cut to Image of Concerned Lab Executive]
Narrator (Voiceover): "Let's break it down. Why the uproar?"
[Zoom in on the Core Change]
Narrator (Voiceover): "At the heart of this issue is a seemingly small but potent change."
[Show Rule Text]
Narrator (Voiceover): "The FDA now categorizes tests as in vitro diagnostic devices (IVDs) when labs are the manufacturers."
[Transition to Regulatory Concerns]
Narrator (Voiceover): "But what's got the lab industry up in arms?
Regulatory nightmares and unanswered questions."
[Show Section on Costs and Benefits]
Narrator (Voiceover): "The FDA estimates compliance costs for the lab industry could hit a jaw-dropping billion-dollar figure."
[Cut to Concerned Lab Professionals]
Narrator (Voiceover): "And this is only part of the problem. Imagine the FDA staff swamped by thousands of applications, with no clear plan to handle them."
[Transition to Crushing Innovation]
Narrator (Voiceover): "Then there's the innovation dilemma. The lab industry fears this regulation will slam the brakes on creativity."
[Show FDA Justification]
Narrator (Voiceover): "While the FDA cites concerns about under-regulation, many in the lab industry argue that existing quality control measures are robust."
[Transition to Compliance Chaos]
Narrator (Voiceover): "Navigating the proposed phased approach is a labyrinth of challenges."
[Show Timeline]
Narrator (Voiceover): "From ending enforcement discretion to premarket review requirements, it's a roadmap to chaos and uncertainty."
[Cut to Lab Innovators]
Narrator (Voiceover): "Innovation thrives when barriers are low, and bureaucracy is minimal. The lab industry dreads that these new regulations will crush that spirit."
[Voiceover Shifts to Firm Tone]
Narrator (Voiceover): "In conclusion, the lab industry is sounding the alarm. They see this regulation as a land grab by overzealous regulators."
[Show Images of Protests or Opposition]
Narrator (Voiceover): "Billions in costs are unaccounted for, and the potential damage to lab industry innovation via LDT tests is nothing short of tragic."
[Voiceover Gains Emphasis]
Narrator (Voiceover): "It's not just about what the FDA says it will do; it's about what they can realistically achieve."
[Closing Shot]
Narrator (Voiceover): "The lab industry isn't taking this lightly. They're gearing up for a battle, ready to protect their turf and the innovative spirit that's been their hallmark."
[Background Music Fades]
This script portrays a strong opposition perspective from a group representing the lab industry, highlighting concerns about costs, regulatory chaos, and potential harm to innovation. It maintains a firm tone throughout while expressing their reservations about the FDA's ability to handle the proposed changes effectively.
BONUS
LOUIS BLACK
Now, instead of an anti-FDA script, which you have just written, a short monolog against the FDA proposal in a similar tone but in the voice of comedian Louis Black.
ChatGPT
[Opening with Louis Black's trademark exasperated tone]
Louis Black: "Ladies and gentlemen, gather 'round, because it's time for a comedy of errors brought to you by the FDA!"
[Expressive Hand Gestures]
Louis Black: "So, the FDA, in all its wisdom, decides it's time to drop a regulatory bomb on the lab-developed test industry. I mean, come on, folks!"
[Mocking Surprise]
Louis Black: "What's their brilliant plan? They say, 'Hey, let's call these tests in vitro diagnostic devices (IVDs) when labs make 'em.'"
[Facepalm]
Louis Black: "Well, ain't that a groundbreaking idea! The kind of idea that must've taken, what, five minutes to come up with?"
[Imitating FDA]
Louis Black: "We've got problems with lab-developed tests, let's just slap the 'IVD' label on 'em, and voila! Problem solved!"
[Sarcastic Applause]
Louis Black: "Give 'em a round of applause, folks! The FDA's done it again!"
[Switching to Mock Seriousness]
Louis Black: "But wait, there's more! The FDA thinks this little change will only cost the lab industry a cool billion dollars or more."
[Rolling Eyes]
Louis Black: "Oh, great! Because, you know, labs have cash lying around like spare change in the sofa cushions."
[Sarcastic Excitement]
Louis Black: "And, here's the best part! The FDA doesn't have a clear plan to handle the flood of applications that'll come their way."
[Incredulous]
Louis Black: "Can you believe it? It's like they're saying, 'Let's launch a thousand ships without a captain and see what happens!'"
[Shaking Head]
Louis Black: "But, hey, innovation, who needs it, right? The FDA's here to put a stop to all that creativity!"
[Mocking Tone]
Louis Black: "Because we all know that innovation happens best when you drown it in paperwork and bureaucracy!"
[Resigned Laughter]
Louis Black: "So there you have it, folks, the FDA's grand plan. It's like they're playing a game of regulatory Jenga, and they're pulling out the pieces left and right."
[Concluding with a Sigh]
Louis Black: "But hey, what do I know? I'm just a comedian. The FDA's the one with all the answers!"
[Exaggerated Eye Roll]
Louis Black: "Good luck, lab industry, you're gonna need it!"
[Louis Black's Trademark Frustrated Gesture]
Louis Black: "And that's the FDA for ya!"
[Exit with a Dramatic Wave]
Louis Black: "I'm Louis Black, and this has been your dose of FDA absurdity. Don't forget to laugh through the tears, folks!"
[End with Louis Black's Signature Exasperated Expression]
This monologue takes a comedic and exasperated approach to critique the FDA proposal, highlighting the absurdity of some of its aspects while maintaining Louis Black's trademark humor.
###
###
All right, let's go back to my original blog article describing the FDA's plan. Write a 5 minute video script explaining it to lab industry experts who are moderately concerned about over regulation or the FDA becoming overloading, but not over the top on this concern.
I suggest a 5 minute video (earlier ones were 3 minutes or less) to allow more detail from the blog article and FDA plan.
ChatGPT
[Opening shot: A laboratory setting with lab technicians working.]
Narrator (Voiceover): "In the world of diagnostics, precision and innovation are key. But what happens when the regulatory landscape shifts?"
[Cut to a close-up of a computer screen displaying the FDA's website.]
Narrator (Voiceover): "On September 29, 2023, the FDA released its much-anticipated regulation to control the lab-developed test industry."
[Cut to the FDA's press release on the computer screen.]
Narrator (Voiceover): "This rule comes after months of speculation and discussions within the industry and among policymakers."
[Transition to a montage of newspaper headlines and articles discussing the FDA's proposal.]
Narrator (Voiceover): "It's a topic that's been making headlines and sparking debates. But what does this FDA proposal mean for the lab industry?"
[Cut to a calm and composed expert in a laboratory coat, standing in a lab.]
Expert: "Hello, I'm here to help shed some light on the FDA's recent proposal and what it might mean for our industry."
[Text on screen: Expert Insights]
Expert: "First, let's address the core change in this proposal. The FDA is making explicit that a test is considered an in vitro diagnostic device (IVD) when its manufacturer is a laboratory."
[Cut to a screenshot of the relevant FDA document.]
Expert (Voiceover): "This seemingly simple change can have significant implications. It means that certain lab-developed tests (LDTs) will now be subject to FDA regulation."
[Cut to the expert holding a printed copy of the FDA's proposal.]
Expert: "The FDA's justification for this change is rooted in concerns about under-regulation, performance variability, and the need for better oversight."
[Cut to an animated graphic showing a timeline.]
Narrator (Voiceover): "Now, let's dive into the proposed phased approach. The FDA suggests a five-stage plan."
[Text on screen: Proposed Phased Approach]
Expert (Voiceover): "In the first stage, they want to end enforcement discretion with regard to Medical Device Reporting (MDR) and correction and removal reporting requirements."
[Cut to a timeline graphic highlighting each stage.]
Expert (Voiceover): "Stage two expands the scope to include requirements like registration and listing, labeling, and investigational use."
[Cut to the expert in front of a whiteboard.]
Expert: "Stage three focuses on Quality System (QS) requirements, particularly for LDTs manufactured within a single Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory."
[Cut to the expert holding a clipboard.]
Expert: "Now, in stage four, things get a bit more serious. It's about ending enforcement discretion for high-risk IVDs offered as LDTs."
[Cut to a shot of a high-tech laboratory machine.]
Expert (Voiceover): "And finally, stage five extends that to moderate and low-risk IVDs, requiring premarket submissions like 510(k) or De Novo requests."
[Cut to the expert in the lab.]
Expert: "But what does all of this mean for us?"
[Cut to a graphical representation of costs and benefits.]
Narrator (Voiceover): "According to the FDA's preliminary analysis, the financial benefits could range from $2 billion to $86 billion, with a best estimate of $22 billion."
[Cut to the expert.]
Expert: "Now, let's talk about the elephant in the room: costs."
[Text on screen: Costs]
Expert: "The FDA acknowledges that compliance costs could be around $6 billion [BQ per year average 20 years, but $30-40B in first years]. And that's where our concerns come in."
[Cut to an animated graphic showing potential consequences.]
Narrator (Voiceover): "With billions at stake, some worry that this could burden the lab industry, lead to delays, and even affect innovation."
[Cut to a shot of lab technicians working diligently.]
Expert: "We've built a thriving industry with a focus on delivering quality diagnostics swiftly. The concern is that additional regulation might slow us down."
[Cut to the expert in front of a laboratory setting.]
Expert: "But let's be clear; we all want to ensure the safety and effectiveness of tests. It's a matter of finding the right balance."
[Text on screen: Finding Balance]
Expert: "The FDA believes that this phased approach provides that balance. They want to prioritize high-risk tests while giving labs time to adapt."
[Cut to an animated graphic summarizing the proposed phases.]
Narrator (Voiceover): "So, what's next?"
[Text on screen: What's Next?]
Expert (Voiceover): "The proposed rule is now open for comments until November 29. It's a chance for our industry to voice concerns, suggest improvements, and influence the final regulations."
[Cut to a shot of the expert reviewing the FDA proposal.]
Expert: "It's essential for all stakeholders, including labs, to participate in this process."
[Cut to the expert in front of a lab backdrop.]
Expert: "In conclusion, the FDA's proposal is a significant development for our industry. While it may bring challenges, it also offers opportunities for collaboration and improvement."
[Text on screen: Collaboration & Improvement]
Expert: "Let's work together to ensure that our industry continues to provide the highest quality diagnostics to those who need them."
[Closing shot: The expert standing confidently in the lab.]
Expert: "Thank you for joining me today, and let's keep the dialogue open as we navigate these changes together."
[Text on screen: Stay Informed]
Narrator (Voiceover): "Stay informed, stay engaged, and let your voice be heard."
[End with the expert's reassuring smile.]
##
This 5-minute video script provides a balanced overview of the FDA's proposal for the lab industry, acknowledging concerns while emphasizing the importance of participation and collaboration during the comment period.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.